GIZ, BASF and Cargill partnership reaches 2,500 smallholder coconut growers

06-02-2013

A program to develop a certified coconut oil supply chain to enhance sustainability and improve the livelihoods of 2,500 coconut growers in the Philippines has been launched. It is a result of a partnership between the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, BASF ...

more

26-02-2010

H. Lundbeck A/S announced it had expanded the agreement with Teva Pharmaceutical Industries Ltd. for Azilect® to cover six markets in Asia - China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines. The Asian market is becoming an increasingly important platform for Lundbeck, ...

more

19-02-2010

An increasing number of Pharmaceutical (Pharma) companies are targeting emerging markets. Indonesia and the Philippines are starting to gain considerable attention thanks to their burgeoning healthcare systems. A recent report by independent market analyst Datamonitor shows that Pharma’s ...

more

05-01-2010

Intercell AG announced the initiation of a pediatric Phase III study for IXIARO/JESPECT in children above 6 months of age travelling from U.S., Europe and Australia to JE‐endemic areas. The vaccine is currently licensed as adult vaccine in Europe, Canada, the United States (IXIARO) and ...

more

22-10-2009

Crucell N.V. announced that detailed results of the Phase II Philippines study of its rabies monoclonal antibody combination (CL 184) were presented at the XX Rabies in the Americas (RITA) Conference in Quebec, Canada. The presentation was given by Dr Beatriz P. Quiambao (MD), Chief Clinical ...

more

25-06-2009

Crucell N.V. announced the results of a second phase II clinical study of its investigational rabies monoclonal antibody combination, which started in May 2008 in the Philippines. Crucell has a collaboration and commercialization agreement with sanofi pasteur, the vaccines division of ...

more

Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer

07-01-2009

YM BioSciences Inc. announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab ...

more

15-05-2008

Crucell N.V. announced that its rabies monoclonal antibody combination product has entered a second phase II clinical study in the Philippines. On 31 March 2008 the company announced the start of a first phase II clinical study in the U.S. The second phase II clinical trial will be a ...

more

24-01-2008

Sinochem International Corporation and Monsanto Company announced that Sinochem and its subsidiaries have signed agreements with Monsanto's Asia and India subsidiaries for the acquisition of Monsanto's butachlor and alachlor businesses and certain other assets. Under the terms of the ...

more

Positive Results Enable Prompt Progression Towards Phase II Studies

04-12-2007

Crucell N.V. announced the results of the second clinical evaluation of their rabies monoclonal antibody cocktail. Data for the Phase Ib study conducted in India which started in April 2007 indicate that the cocktail is well tolerated, provides the expected neutralizing activity and that it ...

more